Purified Anti-human CD28 Antibody *9.3*
The 9.3 monoclonal antibody binds with human CD28, a 44 kD transmembrane glycoprotein typically located on the surface of natural killer cells and plasma cells. CD28 is a member of vital cellular pathways, namely, the cell surface receptor signaling pathway, apoptotic signaling pathway and T cell receptor signaling pathway. Also, in some organisms, it is involved in the positive regulation of interleukin-4 production, is involved in the positive regulation of inflammatory response to antigenic stimulus and promotes isotype switching to IgG isotypes. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands such as PI3-kinase, CD86 and CD80. CD28 is a very popular antibody target, with over 30000 publications in the last decade. CD28 is vital to costimulatory molecules research, typically serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography.
Conjugation
We provide custom conjugation services for this antibody (eg. labeling of cd28 antibody with HRP). A list of available labels can be found in the table below:
For additional information about custom conjugations, please consult our services page here.
AF | AF350, AF488, AF555, AF594, AF647, AF680, AF700, AF750 |
Proteins | HRP, Alkaline Phosphatase, Streptavidin |
Tandems | APC, APC/Cy7, APC/AF750, APC/iFluor™ 700, APC/iFluor™ 750, PE, PE/Cy5, PE/Cy7, PE/AF610, PE/AF700, PE/iFluor™ 594, PE/iFluor™ 647, PE/iFluor™ 700, PE/iFluor™ 750, PE/Texas Red®, PerCP, PerCP/Cy5.5 |
Small Molecules | Biotin |
Traditional Dyes | FITC (fluorescein), TRITC, PacBlue, PacOrange, Cy3, Cy5 |
iFluor | 350, 405, 430, 450, 488, 514, 532, 546, 555, 560, 568, 594, 610, 633, 647, 660, 670, 680, 700, 710, 750, 790, 800, 810, 820, 840, 860, A7 |
mFluor | UV375, UV460, Violet 450, Violet 500, Violet 510, Violet 540, Blue 570, Green 620, Red 700, Red 780 |
For additional information about custom conjugations, please consult our services page here.
Page updated on April 25, 2025